Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Nezi

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.
Nature|August 15, 2014
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial functionAndrea Viale, Piergiorgio Pettazzoni, Costas A Lyssiotis, et al.
Cell Host & Microbe|October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patientsAngeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
The Journal of Experimental Medicine|June 4, 2020
Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cellsTeresa Manzo, Boone M Prentice, Kristin G Anderson, et al.
Ebiomedicine|December 19, 2023
Circulating biomarkers in familial cerebral cavernous malformationFrancesca Lazzaroni, Jennifer M T A Meessen, Ying Sun, et al.
Oncoimmunology|November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanomaMichael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.
Cell Reports|June 21, 2016
In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic CancerAlessandro Carugo, Giannicola Genovese, Sahil Seth, et al.
Nature|March 29, 2019
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancerWantong Yao, Johnathon L Rose, Wei Wang, et al.
Cancer Cell|May 13, 2015
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndromeSimona Colla, Derrick Sek Tong Ong, Yamini Ogoti, et al.
Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.
Nature|August 15, 2014
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial functionAndrea Viale, Piergiorgio Pettazzoni, Costas A Lyssiotis, et al.
Cell Host & Microbe|October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patientsAngeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
The Journal of Experimental Medicine|June 4, 2020
Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cellsTeresa Manzo, Boone M Prentice, Kristin G Anderson, et al.
Ebiomedicine|December 19, 2023
Circulating biomarkers in familial cerebral cavernous malformationFrancesca Lazzaroni, Jennifer M T A Meessen, Ying Sun, et al.
Oncoimmunology|November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanomaMichael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.
Cell Reports|June 21, 2016
In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic CancerAlessandro Carugo, Giannicola Genovese, Sahil Seth, et al.
Nature|March 29, 2019
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancerWantong Yao, Johnathon L Rose, Wei Wang, et al.
Cancer Cell|May 13, 2015
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndromeSimona Colla, Derrick Sek Tong Ong, Yamini Ogoti, et al.
Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.
Pageof 5